Therapy-Related Myeloid Neoplasms in 109 Patients Following Radiation Monotherapy

• DOI: 10.1182/bloodadvances.2021004964
• Publication Date: 2021-09-07T21:58:07Z
• Authors: Anand Ashwin Patel; Alexandra E Rojek; Michael William D...; Howard Weiner; Lucy Ann Godley; Michelle M. Le Beau; Richard A. Larson
• Keywords: Chromosome abnormality; Latency stage; Abnormality

Therapy-related myeloid neoplasms (t-MNs) are a late complication of cytotoxic therapy and defined as distinct entity by the World Health Organization. While link between chemotherapy exposure risk subsequent t-MN is well-described, association radiation monotherapy (RT) less definitive. We analyzed 109 consecutive patients who developed t-MNs after RT describe latencies, cytogenetic profile, mutation analyses, clinical outcomes. The most common abnormality was clonal in chromosome 5 and/or 7, which present 45% patients. median latency from to diagnosis 6.5 years, with shortest balanced translocations. 1-year overall survival (OS) 52% 5-year OS 22% for entire cohort. Patients 7 abnormalities experienced worse (37%) (2%) when compared other groups (p<0.0001). 16 underwent NGS; ASXL1 TET2 were commonly mutated genes (n=4). In addition, 17 germline variant testing 3 carried pathogenic or likely variants. conclusion, have increased frequencies abnormalities, associated poor survival. variants may be monotherapy.